title: Neuroprotective effect of lipoxin A4 methyl ester in a rat model of permanent focal cerebral ischemia.
abstract: Neuroprotective effect of lipoxin A(4) methyl ester (LXA(4) ME) was tested in a rat model of permanent middle cerebral artery occlusion. LXA(4) ME was administrated through intracerebroventricular injection immediately after middle cerebral artery was occluded. Administration of LXA(4) ME ameliorated neurological deficit, reduced infarct volume, attenuated histological damage, and decreased number of apoptotic neuron induced by ischemic insult. These neuroprotective effects of LXA(4) ME were associated with inhibition of neutrophil infiltration, lipid peroxidation, and astrocyte activation. In addition, LXA(4) ME also attenuated proinflammatory cytokines (TNF-alpha and IL-1beta) production. These data suggest that LXA(4) ME protects neuron against permanent cerebral ischemia by inhibiting inflammatory responses.
authors.affiliation: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wu
authors.forename: Xi-Hong
authors.initials: XH
authors.lastname: Ye
authors.forename: Pei-Pei
authors.initials: PP
authors.lastname: Guo
authors.forename: San-Peng
authors.initials: SP
authors.lastname: Xu
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Shi-Ying
authors.initials: SY
authors.lastname: Yuan
authors.forename: Shang-Long
authors.initials: SL
authors.lastname: Yao
authors.forename: You
authors.initials: Y
authors.lastname: Shang
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D004195:Disease Models, Animal; D004660:Encephalitis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D004952:Esters / Q000494:pharmacology*; D007276:Injections, Intraventricular; D015227:Lipid Peroxidation / Q000187:drug effects; D044045:Lipoxins / Q000008:administration & dosage*; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009504:Neutrophils / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects
chemical_list: D004952:Esters; D044045:Lipoxins; D018696:Neuroprotective Agents; C040527:lipoxin A4
references.citation: J Biol Chem. 1997 Mar 14;272(11):6972-8
references.pmid: 9054386
references.citation: Surg Neurol. 2006 Sep;66(3):232-45
references.pmid: 16935624
references.citation: Nat Immunol. 2005 Dec;6(12):1191-7
references.pmid: 16369558
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2007 Mar;76(3):173-80
references.pmid: 17329090
references.citation: J Leukoc Biol. 2008 Sep;84(3):600-6
references.pmid: 18495783
references.citation: Brain Res. 1997 Mar 21;751(2):181-8
references.pmid: 9099804
references.citation: J Am Soc Nephrol. 2002 Oct;13(10):2497-507
references.pmid: 12239238
references.citation: Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):145-56
references.pmid: 15171815
references.citation: J Neurosci. 2009 Mar 25;29(12):3875-84
references.pmid: 19321784
references.citation: J Immunol. 2003 Mar 1;170(5):2688-94
references.pmid: 12594298
references.citation: Neuroscience. 2009 Apr 10;159(4):1309-15
references.pmid: 19185051
references.citation: J Surg Res. 2009 Jul;155(1):104-10
references.pmid: 19285686
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):892-901
references.pmid: 17371805
references.citation: Chin Med J (Engl). 2009 Apr 5;122(7):834-8
references.pmid: 19493399
references.citation: Nat Rev Immunol. 2002 Oct;2(10):787-95
references.pmid: 12360216
references.citation: J Cereb Blood Flow Metab. 1998 Jan;18(1):52-8
references.pmid: 9428305
references.citation: Mol Pharmacol. 2008 Jul;74(1):154-61
references.pmid: 18413658
references.citation: Neurol Res. 2004 Dec;26(8):884-92
references.pmid: 15727272
references.citation: J Exp Med. 2007 Feb 19;204(2):245-52
references.pmid: 17242163
references.citation: J Neuroimmunol. 2007 Mar;184(1-2):53-68
references.pmid: 17188755
references.citation: Curr Opin Neurol. 2009 Jun;22(3):294-301
references.pmid: 19434798
references.citation: Curr Pharm Des. 2008;14(33):3549-64
references.pmid: 19075732
references.citation: J Immunol. 2007 Dec 15;179(12):8533-43
references.pmid: 18056401
references.citation: Am J Respir Crit Care Med. 2008 Sep 15;178(6):574-82
references.pmid: 18583575
references.citation: Anesth Analg. 2007 Feb;104(2):369-77
references.pmid: 17242094
references.citation: Biochemistry. 1995 Nov 7;34(44):14609-15
references.pmid: 7578068
references.citation: J Exp Med. 2000 Apr 3;191(7):1197-208
references.pmid: 10748237
references.citation: FASEB J. 2006 Sep;20(11):1785-92
references.pmid: 16940150
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):163-77
references.pmid: 16125378
references.citation: Inflamm Allergy Drug Targets. 2006 Apr;5(2):91-106
references.pmid: 16613568
references.citation: Inflamm Res. 2007 Aug;56(8):324-33
references.pmid: 17687517
references.citation: Life Sci. 2007 Sep 22;81(15):1211-22
references.pmid: 17904584
references.citation: J Neurochem. 2008 Jun;105(5):1737-45
references.pmid: 18248611
references.citation: Nat Rev Immunol. 2008 May;8(5):349-61
references.pmid: 18437155
references.citation: Glia. 2001 Nov;36(2):180-90
references.pmid: 11596126
references.citation: Prog Neurobiol. 2002 Jun;67(2):161-72
references.pmid: 12126659
references.citation: Thromb Haemost. 2007 Jan;97(1):88-98
references.pmid: 17200775
references.citation: Br J Pharmacol. 2004 Sep;143(1):43-52
references.pmid: 15302682
references.citation: J Periodontal Res. 1999 Oct;34(7):370-3
references.pmid: 10685363